---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-008325"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T05:56:32.607299+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences raises up to $175M in PIPE; extends cash runway into 2028

## Summary
- Upfront gross proceeds ~$75M from ~6.8M common shares and 100K pre-funded warrants; up to ~$100M more from warrant exercise.
- Pricing: common shares at $10.77 (most) and $12.13 for insiders; warrants exercisable at $14.40.
- Warrants expire 60 days after PMN310 SAD topline data announcement or Feb 3, 2031.
- Proceeds to fund Phase 1b Alzheimer's study and subcutaneous PMN310 development; blinded 6-month data expected mid-2026.
- Co-led by Janus Henderson and Ally Bridge Group; CEO and board also participated.

## SEC filing metadata
- accession: 0001104659-26-008325
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/0001104659-26-008325-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/pmn-20260129x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-008325
- JSON: https://secwatch.observer/filing/0001104659-26-008325.json
- Plain text: https://secwatch.observer/filing/0001104659-26-008325.txt

## Key facts
- Material Agreements
  ProMIS Neurosciences Inc. entered into Registration Rights Agreement with each of the PIPE Investors.
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: each of the PIPE Investors
  source text: In connection with the Securities Purchase Agreement, the Company entered into a Registration Rights Agreement with each of the PIPE Investors (the “ Registration Rights Agreement ”), pursuant to which the Company is required to prepare and file a registration statement (the “ Registration Statement ”) with the Securities and Exchange Commission (the “ SEC ”) under the Securities Act, covering the resale of the Common Shares issued to the PIPE Investors under the Securities Purchase Agreement, together with the Warrant Shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/0001104659-26-008325-index.htm
- Material Agreements
  ProMIS Neurosciences Inc. entered into Securities Purchase Agreement with selected investors that qualify as "accredited investors" valued at approximately $75 million (effective 2026-01-29).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: selected investors that qualify as "accredited investors"
  - Value: approximately $75 million
  - Effective: 2026-01-29
  source text: On January 29, 2026, ProMIS Neurosciences Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with selected investors that qualify as “accredited investors” (the “ PIPE Investors ”), as defined in Rule 501(a) of Regulation D promulgated under the United States Securities Act of 1933, as amended (the “ Securities Act ”), for the purpose of raising approximately $75 million in aggregate gross proceeds for the Company (the “ Offering ”) before deducting placement agent fees and other expenses payable by the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/0001104659-26-008325-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.